Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105815 | 0.77 | SLC6A2 (0.41) | KCNH2SLC6A2SLC6A4MAPT | |
| SCHEMBL17123794 | 0.76 | SLC6A2 (0.49) | KCNH2SLC6A2SLC6A4ALOX5 | |
| Hydrochloric Acid SCHEMBL14861970 | 0.75 | SLC6A2 (0.47) | KCNH2SLC6A2SLC6A4ALOX5 | |
| SCHEMBL12093082 | 0.73 | SLC6A4 (0.44) | KCNH2SLC6A2SLC6A4 | |
| SCHEMBL22547322 | 0.73 | MCHR1 (0.44) | KCNH2SLC6A2SLC6A4ALOX5MAPT | |
| SCHEMBL21525510 | 0.69 | ACSL1 (0.44) | KCNH2SLC6A2SLC6A4 | |
| SCHEMBL22547907 | 0.67 | KCNH2 (0.36) | KCNH2SLC6A2SLC6A4ALOX5SCN5A | |
| SCHEMBL14873929 | 0.67 | SLC6A2 (0.47) | SLC6A2SLC6A4GRIN1GRIN2B | |
| SCHEMBL14873951 | 0.65 | HRH1 (0.48) | DRD4SLC6A2SLC6A4 | |
| SCHEMBL17548201 | 0.65 | GRM4 (0.42) | RXRAGRIN1GRIN2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9643970-B2 | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2017-05-09 | — | — | US | disclosed |
| EP-3121178-A1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE | H. Lundbeck A/S (DK) | 2017-01-25 | — | — | EP | disclosed |
| EP-2906562-B1 | PDE9I WITH IMIDAZO PYRAZINONE BACKBONE | LUNDBECK & CO AS H (DK) | 2016-10-05 | — | — | EP | disclosed |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| WO-2013053690-A1 | PDE9I WITH IMIDAZO PYRAZINONE BACKBONE | H. LUNDBECK A/S (DK) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | DRD4 1669/4885KCNH2 2112/4885SLC6A2 903/4885 |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | PDE9A, PDE12, PDE5A | DRD4 1550/4885KCNH2 1820/4885SLC6A2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.